Clene (CLNN) to Release Earnings on Wednesday

Clene (NASDAQ:CLNN) is expected to release its earnings data before the market opens on Wednesday, March 12th. Analysts expect Clene to post earnings of ($1.21) per share and revenue of $0.13 million for the quarter.

Clene Price Performance

Shares of CLNN opened at $4.40 on Tuesday. The company has a market cap of $36.63 million, a PE ratio of -0.83 and a beta of 0.27. Clene has a one year low of $3.82 and a one year high of $10.20. The stock has a 50-day moving average of $4.75 and a 200-day moving average of $5.00.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Benchmark cut their target price on Clene from $90.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Clene in a report on Tuesday, February 25th. Canaccord Genuity Group cut their price objective on Clene from $86.00 to $83.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Clene in a report on Tuesday, February 25th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $55.25.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.